Delays in protease inhibitor use in clinical practice

Journal of General Internal Medicine

Volumn 14, Issue 7, 1999, Pages 395-401

  Fairfield, Kathleen M ^a,b   Libman, Howard ^a   Davis, Roger B ^a   Eisenberg, David M ^a   Phillips, Russell S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Depression; HIV; Injection drug use; Protease inhibitors

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL PRACTICE; DEPRESSION; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PNEUMOCYSTIS PNEUMONIA; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DEPRESSION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PNEUMONIA, PNEUMOCYSTIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; VIRAL LOAD;

EID: 0032788683     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.1999.08198.x     Document Type: Article

References (22)

1. 1. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105-10.
2. 2. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-9.
3. 3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science. 1996;271:1582-6.
4. 4. Cohen OJ, Pantaleo G, Holodnly M, et al. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA. 1995;92:6017-21.
5. 5. Carpenter CCJ, Fischl MA, Hammer SM, et al., for the International AIDS Society. Antiretroviral Therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 1996;276:146-54.
6. 6. Carpenter CCJ, Fischl MA, Hammer SM, et al., for the International AIDS Society. Antiretroviral Therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA. 1997;277:1962-9.
7. 7. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277:145-53.
8. 8. Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clinical Care. 1997;9:51-4,58.
9. 9. Safran C, Rury C, Rind DM, Taylor WC. A computer-based outpatient medical record for a teaching hospital. MD Comput. 1991;8: 291-9.
10. 10. Makadon HJ, Delbanco SF, Delbanco TL. Caring for people with AIDS and HIV infection in hospital-based primary care practice. J Gen Intern Med. 1990;5:446-50.
11. 11. Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med. 1998;158:2257-64.
12. 12. Kleinbaum DG, Kupper LL, Muller KE. Applied Regression Analysis and Other Multivariable Methods. Belmont, Calif: Duxbury Press; 1988.
13. 13. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129:125-37.
14. 14. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, DC: US Department of Health and Human Services. 1998;47(RR-5):43-82.
15. 15. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, Ga: Centers for Disease Control and Prevention; 1997:9 (No. 1).
16. 16. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338: 853-60.
17. 17. Detels R, Munoz A, McFarlane G, et al. Increased survival time to AIDS and death associated with use of combined therapy in the multicenter AIDS cohort study. Presented at the 5th Conference on Retroviral Opportunistic Infection, Feb 1-5, 1998. Abstract 115.
18. 18. McNaghten AD, Hanson DL, Jones JL, Ward JW, Dworkin MS. The effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS. Presented at the 5th Conference on Retroviral Opportunistic Infection, Feb 1-5, 1998. Abstract 81.
19. 19. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544-6.
20. 20. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998; 280:547-9.
21. 21. Mayne TJ, Vittinghoff E, Chesney MA, Barrett DC, Coates TJ. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med. 1996;156:2233-8.
22. 22. Singh N. Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8: 261-9.